newsfilter
← Latest News
Business Wire·

Quanterix Releases Financial Results for the Third Quarter of 2026

QTRX
  • Quanterix reported Q3 2026 revenue of $35.0 million, a 6.3% sequential increase.
  • The company ended the quarter with $80.7 million in cash, cash equivalents, marketable securities, and restricted cash.
  • GAAP gross margin was 38.6%, down 90 basis points year-over-year, while non-GAAP adjusted gross margin was 47.4%, up 150 basis points.
  • Net loss for the quarter was $21.6 million, a 35.6% improvement compared to the prior year.
  • Adjusted EBITDA loss was $12.2 million, representing a 2.4% decline versus the prior year.
  • The company narrowed its 2026 total revenue guidance to a range of $142-146 million.
  • Quanterix expects 2026 adjusted gross margins to be between 48% and 50% and anticipates ending the year with approximately $70 million in cash.
  • Jim Gute was named Chief Commercial Officer in mid-August 2026, and Dr. Yuri Fesko became the first Chief Medical Officer in September 2026.
  • Medicaid members and state employees in Florida gained coverage for Quanterix's LucentAD® Complete blood-based test starting November 1, 2026.
  • New commercial partnerships were established with Sherman Abrams Lab in New York and TruPath in Mississippi.
  • Innovita Biological Technology Co. expanded access to Quanterix's biomarker testing in China using HD-X and SR-X instruments.
  • The PhenoCode™ 2.0 Molecular Barcoding Kit entered full commercial release, with the TIME panel and high-plex ADC panel scheduled to ship in early 2027.
  • Quanterix launched new assay menu options for its SIMOA® platform targeting Alzheimer's and neurodegenerative diseases.
  • The company's Accelerator Lab began accepting requests for custom ADC panel development.
  • The conference call to discuss these results is scheduled for November 9, 2026, at 8:30 AM ET.